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Abstract
Background -: The chronic use of opioids prior to surgery leads to lowered pain thresholds and
exaggerated pain levels after these procedures. Several mechanisms have been proposed to explain this
heightened sensitivity commonly termed opioid-induced hyperalgesia (OIH). Most of these proposed
mechanisms involve plastic events in the central or peripheral nervous systems. Alterations in the
abundance of peripheral mediators of nociception have not previously been explored.
Results -: In these experiments mice were treated with saline (control) or ascending daily doses of
morphine to generate a state of OIH followed by hind paw incision. In other experiments morphine
treatment was initiated at the time of incision. Both mechanical allodynia and peri-incisional skin cytokine
levels were measured. Myeloperoxidase (MPO) assays were used to determine neutrophil activity near
the wounds. The cytokine production inhibitor pentoxifylline was used to determine the functional
significance of the excess cytokines in previously morphine treated animals. Mice treated chronically
treated with morphine prior to incision were found to have enhanced skin levels of IL-1β, IL-6, G-CSF, KC
and TNFα after incision at one or more time points compared to saline pretreated controls. The time
courses of individual cytokines followed different patterns. There was no discernable effect of chronic
morphine treatment on wound area neutrophil infiltration. Pentoxifylline reduced cytokine levels and
reversed the excess mechanical sensitization caused by chronic morphine administration prior to incision.
Morphine treatment initiated at the time of incision did not lead to a generalized enhancement of cytokine
production or nociceptive sensitization in excess of the levels observed after incision alone.
Conclusion -: The enhanced level of nociceptive sensitization seen after incision in animals chronically
exposed to morphine is associated with elevated levels of several cytokines previously reported to be
relevant to this incisional pain model. The cytokines may be functional in supporting nociceptive
sensitization because pentoxifylline reverses both peri-incisional skin cytokine levels and OIH. Opioid
administration beginning at the time of incision does not seem to have the same cytokine enhancing effect.
Approaches to postoperative pain control involving a reduction of cytokines may be an effective way to
control excessive pain in patients chronically using opioids prior to surgical procedures.
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Introduction
While opioids are a mainstay of treatment for chronic
pain and are second only to NSAIDS terms of the number
of prescriptions written for common chronic pain syn-
dromes [1], problems with long term use are becoming
better recognized. Tolerance and dependence on these
drugs have been studied for some time. More recently, the
phenomenon of opioid-induced hyperalgesia (OIH) has
come under study (see ([2-6]) for recent reviews). This
form of hyperalgesia has been noted in human popula-
tions maintained long term with methadone [7-11],
treated with morphine for back pain [12], and infused
with the potent short-acting opioid remifentanil in exper-
imental pain laboratories [13-18]. Based largely on stud-
ies in laboratory animals, several mechanisms have been
suggested including sensitization of peripheral nocicep-
tors [19-21], enhanced production and central release of
excitatory amino acid (EAA) and peptide neurotransmit-
ters [22,23], diminished uptake of EAA neurotransmitters
in the spinal cord [24], and enhanced descending facilita-
tion of spinal nociceptive neurotransmission from the
rostral ventromedial medulla (RVM) [25]. Many of these
responses represent mechanistic counterbalances to the
acute effects of opioid receptor activation.
Clinically, post-incisional pain has been observed to be
more severe in chronically opioid consuming patients
[26]. These patients consume several times the normal
doses of opioids in the perioperative period and do not
always achieve the same level of comfort as previously
opioid naïve patients [26,27]. The situation is sufficiently
widely recognized that guidelines for the management of
these patients have been provided [28]. Several groups
have studied the phenomenon of opioid-exaggerated
post-incisional pain in laboratory models. Our group has
studied the problem in a rat model of incisional pain in
which the animals were treated chronically with mor-
phine prior to the incisional being made [29]. In this
model it was observed that opioid treated animals dis-
played mechanical allodynia in excess of saline treated
ones with the difference not appearing until 2 days after
incision, reaching maximum at 3 days and persisting for
at least 7 days. Celerier et al. observed that the administra-
tion of high dose opioids at the time of incision generated
hind paw peri-incisional sensitization in excess of what
was observed when using inhalational anesthesia alone
[30]. Again, the opioid-induced excess hyperalgesia was
prominent for up to 7 days following incision. The mech-
anisms responsible for the opioid-induced excess in noci-
ceptive sensitization have not been fully explored.
Recently we observed that the acute systemic administra-
tion of opioids like morphine can substantially reduce the
abundance of specific cytokines accumulating in the peri-
incisional tissue [31]. Several of these cytokines including
interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α
(TNFα) have been observed to support enhanced nocice-
ptive sensitivity in various rodent models [32-34]. Both
keratinocytes and infiltrating neutrophils were observed
to be producing these cytokines near the wound edges
[31]. Because it appears that the chronic effect of opioids
is sometimes to cause effects paradoxically opposite to the
acute effects of these drugs, we hypothesized that mice
chronically treated with opioids would display exagger-
ated levels of skin cytokine production after hind paw
incisions. This would explain some portion of the exag-
gerated nociceptive sensitization seen in these animals.
Such observations would be novel and might suggest
approaches to better controlling pain in vulnerable clini-
cal populations.
Results
3.1 Effects of chronic morphine treatment on post-
incisional mechanical sensitization
The mechanical nociceptive thresholds for mice at base-
line and after 4 days of morphine (chronic morphine) or
saline treatment were first measured. In Figure 1A it can be
seen that prior to incision morphine treated mice devel-
oped mechanical allodynia while saline treated mice had
no change in withdrawal thresholds. If no hindpaw inci-
sions were made, morphine pre-treated mice recovered
from this allodynia to achieve near baseline withdrawal
thresholds over the following 72 hours. Other data in the
figure demonstrate that incision, as expected, caused a
profound but transient decrease in nociceptive thresh-
olds. While these mice also recovered from the allodynia,
mice pretreated with morphine then incised had a slower
course of recovery. Specifically, the morphine pretreated/
incised mice had lower mechanical withdrawal thresholds
than the saline/incised mice at least to 72 hours post-inci-
sion.
Additional experiments were completed in which chronic
daily saline or morphine treatment was initiated at the
time of incision and continued for 4 days according to our
established ascending dose protocol. This protocol was
designed to be similar to the titration of opioids which
might occur post-tissue injury. At the 72 and 120 hour
time points after incision, nociceptive thresholds for the
morphine and morphine/incision treatment groups were
not statistically different (Figure 1B). Previous experimen-
tation established that the 120 hour time point was the
time point of maximum morphine-induced sensitization
in this model [35]. Thus we did not detect an additive
nociception enhancing effect of chronic morphine with
incision using this paradigm.Molecular Pain 2008, 4:7 http://www.molecularpain.com/content/4/1/7
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Mechanical nociceptive thresholds after drug pretreatment and hindpaw incision Figure 1
Mechanical nociceptive thresholds after drug pretreatment and hindpaw incision. Panel A displays the mechanical 
thresholds of mice in four different treatment groups: saline pretreatment/no incision, saline pretreatment/incision, morphine 
pretreatment/no incision, morphine pretreatment/incision. The values labeled pre-incision represent the nociceptive thresh-
olds measured after 4 days of saline or morphine treatment but prior to hind paw incision. In panel B data are presented rep-
resenting mechanical nociceptive thresholds in mice undergoing saline or morphine treatment beginning at the time of incision. 
Nociceptive thresholds were measured immediately before that day's dose of morphine. The statistical analysis presented 
reflects the results of two-way ANOVA comparing saline/incision values to morphine/incision ones. *p < 0.05, **p < 0.01, N = 
6/group.Molecular Pain 2008, 4:7 http://www.molecularpain.com/content/4/1/7
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3.2 Effects of chronic morphine treatment on post-
incisional cytokine generation
In other groups of mice, the skin levels of 5 cytokines were
measured using the chronic morphine prior to incision
paradigm. Those data are presented in Figure 2. In the
absence of incision, the treatment of mice with morphine
for 4 days did not alter the baseline skin levels of any of
these cytokines compared with saline pretreated animals.
Hind paw incision did lead to increases in the skin levels
of all 5 cytokines, though the magnitude of the changes
and the time course of expression was particular to each
mediator. The expression patterns observed for these 5
mediators were similar to those previously reported by
our laboratory after incision for non-opioid treated mice
[31,36]. For all of the tested cytokines, IL-1β, IL-6, TNFα,
G-CSF and KC, chronic morphine treatment prior to inci-
sion lead to an enhanced tissue level of cytokine com-
pared with levels in saline treated then incised mice at one
or more time points. Only for the cytokine, IL-6, was there
no significant difference between the saline and mor-
phine pretreated incised groups 72 hours after incision,
the point at which the behavioral differences were maxi-
mal (Figure 1). The magnitude of the cytokine increase
after incision was up to 5-fold larger in morphine treated
than saline treated groups (G-CSF, 72 hours after inci-
sion).
Additional experiments measuring skin cytokine levels
from mice undergoing morphine treatment beginning at
the time of incision failed to demonstrate any significant
alterations in these levels when compared saline, mor-
phine or saline/incision conditions (Figure 3). Addition-
ally, the overall cytokine levels in the skin surrounding the
wounds was much lower than observed in the experi-
ments presented in Figure 2.
3.3 Effects of chronic morphine treatment on post-
incisional MPO activity
Because infiltrating neutrophils are a potential source of
cytokines in incisional wounds and because acute mor-
phine administration can alter neutrophil infiltration
[31], we sought to determine whether the morphine-
related differences in cytokine levels were attributable to
differences in the peri-incisional levels of these infiltrating
cells. We chose for these measurements the myeloperoxi-
dase assay (MPO) which has excellent correlation with
immunohistochemical neutrophil counts in these mouse
hind paw incisions [31]. In Figure 4 data are presented
showing that incising the hind paw does lead to a rapid
but transient rise in neutrophil skin abundance. However,
chronic morphine pretreatment did not significantly alter
the degree of infiltration when compared with saline pre-
treated mice. Specifically, MPO levels were not higher in
the skin of morphine treated then incised skin when com-
pared with saline treated then incised skin at the 2, 24 or
72 hour time points when the levels of specific cytokines
were enhanced (Figure 2).
3.4 Pentoxifylline effects on morphine enhanced post-
incision allodynia and cytokine generation
While we had observed to this point a correlation between
incision area cytokine levels and the enhancement in
post-incision allodynia caused by chronic morphine
administration, we had no functional evidence for the
participation of these substances. We therefore adminis-
tered the broad spectrum cytokine production inhibitor
pentoxifylline on a daily basis after incisions were made.
The pentoxifylline dose (50 mg/kg) and daily injection
schedule chosen for these experiments has been shown by
others to reduce nociceptive sensitization in mouse and
rat models of neuropathic pain [37,38]. In Figure 5 data
are presented demonstrating that pentoxifylline adminis-
tered daily after the time of hind paw incision completely
eliminated the morphine-enhancement of nociception
normally observed at 72 hours. There was no effect on the
mechanical nociceptive thresholds of mice that under-
went hind paw incision after chronic saline pretreatment.
In additional experiments we observed that pentoxifylline
reduced skin cytokine levels 72 hours after incision in
morphine pretreated mice. The levels were reduced by
74%, 55% and 53% for G-CSF, IL-1β and KC respectively
(p < 0.05 vs. vehicle-treated mice). For IL-6 and TNFα,
pentoxifylline failed to significantly reduce cytokine lev-
els.
Discussion
Opioid-induced hyperalgesia (OIH) is a state of paradox-
ically enhanced pain sensitivity observed in both humans
and animals after chronic exposure to opioids including
morphine, oxycodone, fentanyl, heroin and others. To-
date most explorations of this phenomenon's mechanism
have focused on alterations in functional elements within
the central nervous system and to a lesser degree neuro-
plastic changes involving primary afferent sensory neu-
rons [2]. Our studies were focused further in the periphery
and involved opioid effects on skin cytokine levels both
before and after hindpaw incision. Peripheral cytokine
production had not prior to this time been implicated in
the mechanism of OIH. Our results using the C57BL/6
strain of mice reproduced those we had previously
reported for rats in that morphine treatment both lead to
enhanced nociceptive sensitivity in unperturbed animals,
and significantly enhanced the sensitization of hindpaws
for several days after incision [29]. More importantly, we
went on in the present studies to show that the peri-inci-
sional expression of cytokines previously demonstrated to
be inhibited by morphine given acutely before incision
[31] were moderately to strongly enhanced in the tissues
of mice chronically pretreated with morphine. TheseMolecular Pain 2008, 4:7 http://www.molecularpain.com/content/4/1/7
Page 5 of 12
(page number not for citation purposes)
Peri-incisional skin cytokine levels after saline or morphine pretreatment Figure 2
Peri-incisional skin cytokine levels after saline or morphine pretreatment. The figure displays the mechanical thresh-
olds of mice in four different treatment groups: saline pretreatment/no incision, saline pretreatment/incision, morphine pre-
treatment/no incision, morphine pretreatment/incision. The cytokine levels were assessed at time points out to 72 hours after 
incision based on the results of the experiments presented in Figure 1. The statistical analysis presented reflects the results of 
two-way ANOVA comparing saline/incision values to morphine/incision ones over the 2 to 72 hour time period. *p < 0.05, **p 
< 0.01, N = 8/group.Molecular Pain 2008, 4:7 http://www.molecularpain.com/content/4/1/7
Page 6 of 12
(page number not for citation purposes)
Peri-incisional skin cytokine levels for mice treated with saline or morphine beginning at the time of incision Figure 3
Peri-incisional skin cytokine levels for mice treated with saline or morphine beginning at the time of incision. 
The figure displays cytokine measurements from mice in four different treatment groups: saline, incision/saline, no incision/
morphine, incision/morphine. The cytokine levels were assessed at 120 hours after the incisions were made (18 hours after the 
last dose of morphine). Statistical analysis was performed to detect differences between each set of conditions. N = 8/group.Molecular Pain 2008, 4:7 http://www.molecularpain.com/content/4/1/7
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cytokines included IL-1β, IL-6, TNFα, G-CSF and KC. Of
these, only IL-6 was not elevated in the previously mor-
phine treated mice compared to saline treated mice 72
hours after incision, the time point at which the difference
in mechanical sensitization was maximal. The broad spec-
trum cytokine inhibitor pentoxifylline reduced both the
excess cytokines and excess sensitization measured in the
morphine treated animals. The specific site of action of
pentoxifylline was not determined, though pentoxifylline
has been noted to reduce cytokine production by kerati-
nocytes in culture [39] as well as after ultraviolet light
burns and psoriatic skin [40,41]. Finally, we demon-
strated that the initiation of morphine treatment at the
time of incision did sensitize the hind paws of mice. How-
ever, there did not appear to be any interaction of mor-
phine administration with nociceptive sensitization in
this context. Furthermore, morphine administered under
these circumstances did not lead to any significant differ-
ences in wound area cytokine levels. Taken as a whole, our
data suggest that chronic morphine treatment prior to
incision leads to excess production of cytokines thus
enhancing nociceptive sensitization after incision.
Administration of morphine beginning at the time of inci-
sion does sensitize mice, but this is not in excess of what
is seen with morphine treatment of incision naïve mice,
and there is little enhancement of cytokine production.
Thus cytokine mediation of exaggerated post-incisional
nociception is more relevant to the treatment of chroni-
cally opioid consuming patients than otherwise opioid
naïve patients being treated for postoperative pain.
A range of mechanisms causing OIH have been proposed
and recently reviewed [2]. The principal mechanisms cur-
rently considered responsible for OIH include those lead-
ing to enhanced function or activity of afferent fibers,
second order or projection neurons and descending facil-
itory fibers from the brainstem. For example, chronic
morphine treatment leads to the up-regulation of produc-
tion and release of neurotransmitters by primary afferent
nerve fibers [42,43]. Once released, glutamate reuptake
systems in the spinal cord function less efficiently by vir-
tue of lower levels of expression of neuronal and glial
glutamate reuptake transporters [24]. Also, it appears that
for a given level of primary neurotransmitter like gluta-
mate or substance P that more nociception related behav-
ior is generated in mice having been treated for several
days with morphine. Finally, descending facilitation from
the RVM is enhanced in chronically morphine treated ani-
mals constituting an independent pathway for facilitation
of nociceptive signal transmission [25]. In our own previ-
ous studies we had implicated beta-2 adrenergic receptors
located on peripheral nerve terminals as being linked to
OIH [21]. It should be recognized that one key feature
separating our observations of cytokine participation in
post-incisional OIH versus most other observations is that
this peripheral cytokine mechanism only seems to be
operative when tissue has been damaged. We failed to
find morphine-induced differences in skin cytokine levels
prior to incision and thus cannot invoke these mediators
Mechanical allodynia after incision as affected by morphine  and pentoxifylline Figure 5
Mechanical allodynia after incision as affected by 
morphine and pentoxifylline. In these experiments mice 
were subjected to nociceptive testing of the hind paw to 
establish the baseline threshold. Mice were then pre-treated 
with either saline or morphine for 4 days prior to hind paw 
incisions being made. After incision, groups of mice were 
treated daily with daily intraperitoneal saline or pentoxifylline 
as described in Methods. Nociceptive testing 72 hours after 
hind paw incision (2 hours after the last dose of pentoxifyl-
line). **p < 0.01, N = 8/group.
Myeloperoxidase (MPO) activity after hind paw incisions Figure 4
Myeloperoxidase (MPO) activity after hind paw inci-
sions. For these experiments MPO activity was measured in 
peri-incisional skin as an index of infiltrating neutrophil activ-
ity. Skin was harvested from separate groups of mice at the 
indicated time points and processed for MPO assays as 
described in Methods. The time course for analysis was the 
same as that used for the behavioral and cytokine assays. Sta-
tistical analysis failed to detect between group differences at 
any of these time points. N = 8/group.Molecular Pain 2008, 4:7 http://www.molecularpain.com/content/4/1/7
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as supporting hyperalgesia observed in uninjured mice.
This pattern of expression distinguishes our observations
from those of others who found upregulation of IL-1β, IL-
6 and TNFα in spinal cord microglia after morphine treat-
ment even without additional trauma [44,45].
Our previous studies used immunohistochemical tech-
niques to demonstrate that both infiltrating neutrophils
and peri-incisional keratinocytes produce the cytokines
we measured as elevated after incision [31]. However, as
was the case in our previous experiments using acute mor-
phine administration, the degree of peri-incisional neu-
trophil infiltration did not correlate with peri-incisional
cytokine levels. Importantly, chronic morphine treatment
was not seen to alter wound area neutrophil infiltration.
Thus a simple lessening of neutrophil migration does not
seem to be the explanation for the changes in inflamma-
tory mediators observed in our experiments. The function
of the infiltrating cells was not, however, directly assessed.
Systemic opioid administration has been noted to alter
immune system functioning in a number of ways [46].
Future studies addressing this issue will need to address at
least two possible mechanisms. The first mechanism
involves the participation of peripheral afferent neurons
in controlling keratinocyte cytokine production. The sec-
ond focuses on opioid actions on the keratinocytes them-
selves. Addressing neural mechanism first, chronic opioid
exposure up-regulates the production of SP and CGRP at
the level of both mRNA and protein [22,42,43]. Though
commonly thought of participating only in augmenting
nociceptive signal transmission, these neuropeptides act
on keratinocytes to enhance the production of IL-1β, IL-6,
TNFα and other cytokines [47]. Thus the enhanced avail-
ability and release of these neuropeptides after incision
might explain the augmented levels of cytokines in the
incisional wounds of morphine treated mice. Second, opi-
oid receptors are found on keratinocytes, and keratinoc-
ytes produce opioid peptides [48,49]. These receptors
have clear roles in modulating keratinocyte differentia-
tion, wound healing, and inflammatory responses [50].
While little investigation has focused directly on opioid
modulation of keratinocyte cytokine production, it could
be hypothesized that chronic exposure of keratinocytes to
opioids could alter their cytokine producing capacity thus
leading to enhanced cytokine levels after incision. This
possibility could be addressed directly.
Our studies suggest that some of the cytokines analyzed
may be of special functional interest. The cytokines most
likely to be involved in supporting OIH in our incisional
model include IL-1β, G-CSF and KC. For all three of these
cytokines peri-incisional skin levels were augmented in
morphine treated mice after incision to levels above those
observed in the opioid naïve animals. Furthermore, the
cytokine production inhibitor pentoxifylline reduced the
skin concentration of all three of these cytokines by >50%
in the morphine treated animals three days after incision
at the same time as pentoxifylline reversed the excess sen-
sitization of the hind paws. A variable degree of informa-
tion is available from the literature to assist in interpreting
these observations. With respect to IL-1β, detailed work
has been provided showing that sub-picogram quantities
of subcutaneous IL-1β cause mechanical allodynia. This
allodynia is probably mediated by activation of central
metabotropic glutamate receptors [51,52]. Thus, excess
levels of this cytokine might reasonably be expected to
enhance nociception. For KC, there appears to be little
information concerning the direct effects of KC on nocic-
eptive thresholds. On the other hand, investigators have
linked this cytokine to the recruitment of opioid peptide
expressing neutrophils in inflamed skin. Blockade of KC
activity reduced this peripherally mediated anti-nocicep-
tion [53]. However, given the lack of effect of chronic
morphine treatment on neutrophil recruitment in the
incisional pain model, it is unclear if the previously
reported KC mediated chemoattractant effects are impor-
tant to our observations. Lastly, there is little work describ-
ing possible effects of G-CSF on nociceptive thresholds in
control animals or in models of tissue injury. Of note,
however, is that the subcutaneous administration of G-
CSF in humans can cause a psoriasis-like inflammatory
dermatitis. Analysis of G-CSF induced lesions revealed
evidence of inflammation and elevated levels of cytokines
including IL-8, IL-12 and TNFα [54]. Though we followed
levels of several mediators, it is possible that additional
cytokine mediators participate in the chronic morphine
administration post-incision exacerbation of sensitization
as only a small subset of all known cytokines were meas-
ured in our studies.
Excessive and difficult to treat pain after surgery has been
noted for patients chronically consuming opioids. For
example, de-Leon Casasola demonstrated in a series of
clinical investigations that chronic opioid consuming
patients require approximately three times greater doses
of epidural opioids to control pain after surgical proce-
dures, and that these patients tend to have more serious
pain for a prolonged period after their operations
[27,55,56]. Looking at required doses of parenteral mor-
phine, Rapp et al. came to many of the same conclusions,
namely that about three times as much opioid was
required to control pain in chronic opioid consuming
patients [26]. Importantly, it was also observed that opi-
oid side effects were greater and the degree of pain relief
was poorer despite the enhanced doses. More recently it
was shown that chronic back pain sufferers develop meas-
urable hyperalgesia after only one month of opioid
administration [12]. Reviews are available further charac-
terizing the problem and making suggestions for postop-Molecular Pain 2008, 4:7 http://www.molecularpain.com/content/4/1/7
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erative management of pain in chronically opioid
consuming patients [28,57]. However, very little work has
been done specifically directed at evaluating analgesic
techniques of potential benefit to the chronic opioid con-
suming patient.
Conclusion
Along with exacerbated post-incisional nociception
comes excess cytokine production in animals adminis-
tered morphine on a chronic basis. The excess incisional
area cytokine production may explain the enhanced noci-
ception in laboratory animals and by extension may
explain some amount of the excess surgical pain suffered
by humans chronically consuming opioids. This work
provides a rational basis on which to design therapies
aimed at reducing OIH as it impacts postoperative pain.
Our work suggests that strategies designed to reduce the
production of cytokines globally or perhaps reduce the
production of several specific cytokines may be of benefit
to opioid consuming patients. Our results to-date do not
shed light on the required opioid doses or treatment dura-
tions which might be most closely associated with excess
post-incisional cytokine production. In addition, different
opioids such as morphine and buprenorphine have differ-
ing abilities to alter other aspects of immune function.
Thus different opioids might have differing intrinsic abil-
ities to control wound area inflammatory mediators [46].
As enthusiasm for the use of opioids for the treatment of
chronic pain grows, the number of patients using opioids
prior to surgical procedures is likely to rise. Therefore, the
need for better postoperative pain management tech-
niques applicable to this population is of rapidly increas-
ing importance.
Methods
Animal use
All experimental protocols were reviewed and approved
by Veterans Affairs Palo Alto Healthcare System institu-
tional animal care and use committee prior to the initia-
tion of work. Male mice 12–14 weeks old of the C57Bl/6J
strain were kept under standard conditions with a 12 h
light/dark cycle, an ambient temperature of 22±1°C and
allowed food and water ad libitum. Mice were obtained
from Jackson Laboratories (Bar Harbor, MA) and were
kept in our animal facility a minimum of 1 week prior to
use in experiments.
Hind paw incision
The hind paw incision model was used as modified for
mice [58]. We have used this model previously in order to
study cytokine levels following incision [31,36]. Briefly,
mice were anesthetized using isoflurane 2–3% delivered
through a nose cone. After sterile preparation with alco-
hol, a 0.5 cm longitudinal incision was made with a #15
scalpel on the plantar surface of one hind paw. This inci-
sion was sufficiently deep to divide the plantaris muscle
longitudinally. After briefly holding pressure to stop any
active bleeding, a single 6-0 nylon suture was placed and
antibiotic ointment applied. Mice were then returned to
their cages on soft bedding. Nociceptive testing and tissue
harvest took place at time points up to 120 hours after
incision.
Drug administration
For some groups of mice, morphine or saline vehicle was
administered prior to incision. Mice received either saline
injections twice per day or morphine on an ascending
schedule: Day 1, 10 mg/kg twice per day; Days 2–3, 20
mg/kg twice per day; Day 4, 40 mg/kg twice per day. To
accomplish this, 100 μl 0.9% NaCl with or without mor-
phine (Sigma Chemical, St. Louis, MO) was injected sub-
cutaneously into the skin of the back at the required times.
Incision and nociceptive testing procedures began approx-
imately 18 hours after the final dose of morphine or
saline. This morphine administration protocol has been
used extensively by the lab in studying opioid tolerance,
dependence and hyperalgesia [21,59,60]. Alternatively,
some groups of mice received the same saline or ascend-
ing morphine treatment beginning with the first injection
at the time of hind paw incision or sham incision surgery.
In additional experiments pentoxifylline (Sigma) was
administered after chronic pre-incisional saline or mor-
phine treatments followed by hind paw incision. This
drug was dissolved in 0.9% NaCl and injected intraperito-
neally to mice at the time of hind paw incision and 24, 48
and 70 hours after the incisions were made. The dose used
was 50 mg/kg.
Nociceptive testing
Mechanical allodynia was assayed using nylon von Frey
filaments according to the "up-down" algorithm
described by Chaplan et al. [61] as we have used previ-
ously to detect allodynia in mice [36,62,63]. In these
experiments mice were placed on wire mesh platforms in
clear cylindrical plastic enclosures 10 cm in diameter and
40 cm in height. After 15 minutes of acclimation, fibers of
sequentially increasing stiffness were applied 1 mm lateral
to the central wound edge, pressed upward to cause a
slight bend in the fiber and left in place 5 sec. Withdrawal
of the hind paw from the fiber was scored as a response.
When no response was obtained the next stiffest fiber in
the series was applied to the same paw; if a response was
obtained a less stiff fiber was applied. Testing proceeded
in this manner until 4 fibers had been applied after the
first one causing a withdrawal response allowing the esti-
mation of the mechanical withdrawal threshold [64]. This
data fitting algorithm allowed the use of parametric statis-
tics for analysis. This assay is sufficiently sensitive to detect
mechanical thresholds as low as 0.02 g [21].Molecular Pain 2008, 4:7 http://www.molecularpain.com/content/4/1/7
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Cytokine analysis
To obtain skin samples for cytokine quantification ani-
mals were first sacrificed by CO2 asphyxiation and an
ovular patch of full-thickness skin providing 1.5 mm mar-
gins surrounding the hind paw incisions was collected by
sharp dissection. Patches from each hind paw contained
approximately 12 mg tissue. These samples were placed
immediately into ice cold 0.9% NaCl containing a cock-
tail of protease inhibitors (Complete™, Roche Applied Sci-
ence, Indianapolis, IN). Approximately 750 μl inhibitor
containing saline was used per 25 mg tissue. The samples
were homogenized using a Polytron device (Brinkman
Instruments Inc., Westbury, NY), then centrifuged for 10
min at 12,000 times gravity at 4°C. Supernatant fractions
were kept frozen at -80°C until use. An aliquot was sub-
jected to protein assay (DC Protein Assay, Bio-Rad Labo-
ratories, Hercules, CA).
For the cytokine assays, custom Bio-Rad (Bio-Rad labora-
tories, Hercules, CA) Bio-Plex cytokine analysis kits were
used in conjunction with the Bio-Plex system array reader
according to the manufacturer's directions as described
previously [36]. The specific cytokines were chosen based
on our previously reported results and included IL-1β, IL-
6, G-CSF, KC and TNFα [31,36]. Samples were diluted 1:2
prior to analysis in the buffer supplied, and all samples
were run in duplicate or triplicate in each assay. We dem-
onstrated previously that the dynamic range of sensitivity
of this assay was sufficient to measure both baseline and
incision-stimulated levels of the chosen cytokines [36].
Standard curves for each of the analyzed substances were
included in each run, and sample concentrations were cal-
culated using Bio-Plex Manager software.
Myeloperoxidase (MPO) assay
MPO activity was measured as a biochemical index of
neutrophil recruitment in the wound edge samples, and
showed excellent correlation with immunohistochemical
neutrophil counts in previous studies [31]. Excised skin
samples were washed in PBS and homogenized in 1 ml 50
mM potassium phosphate-buffer solution with 0.5% hex-
adecyl trimethyl ammonium bromide (Sigma Chemical
Co., St. Louis, MO) and 5 mM EDTA. The samples were
then homogenized as above and centrifuged at 12,000
rpm at 4°C. MPO activities in the supernatants were then
assayed using a peroxidase assay kit (Anaspec, San Jose,
CA) along with supplied standards according to the man-
ufacturer's instructions. The data were expressed as MPO
activity in mU per mg protein in the supernatant samples.
Statistical analysis
Analysis of repeated parametric measures was accom-
plished using a one-way ANOVA analysis of variance fol-
lowed by post-hoc Dunnett's testing or a two-way ANOVA
followed by Bonferroni testing. A value of p < 0.05 was
taken to be significant. All data are presented as means +/
- S.E.M. unless otherwise noted.
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